蛋白酶体抑制剂开发商QLi5获得逾620万欧元增资，推进针对癌症、炎症和自身免疫疾病的蛋白酶体抑制剂ADC平台-动脉网

Max Planck Spin-off QLi5 receives Multi-million Euro Investment from Qurient Therapeutics

D-Pharm 等信源发布 2026-01-29 13:55



可切换为仅中文







QLi5 Therapeutics GmbH (QLi5), a spin-off from the Max Planck Institute for Biochemistry, has successfully completed a capital increase totaling over 6.2 million Euro. This strategic investment, significantly backed by the Korean biotech company Qurient and by QLi5 co-founder and Nobel laureate Prof.

QLi5治疗公司（QLi5），作为马克斯·普朗克生物化学研究所的衍生公司，已成功完成总额超过620万欧元的增资。这项战略性投资得到了韩国生物技术公司Qurient以及QLi5联合创始人、诺贝尔奖得主教授的大力支持。

Dr. Robert Huber, is intended to decisively advance the development of QLi5's pioneering Proteasome Inhibitor (PI)-based Antibody-Drug Conjugate (ADC) platform..

罗伯特·胡伯博士旨在大力推进QLi5公司基于蛋白酶体抑制剂（PI）的开创性抗体药物偶联物（ADC）平台的开发。

QLi5 Therapeutics is developing a next generation of proteasome inhibitors based on a novel, non-covalent mechanism of action. Developed in close collaboration with Nobel laureate Robert Huber at the Max Planck Institute for Biochemistry, the platform is designed to enable highly potent and selective targeting of the proteasome, while offering improved pharmacokinetic properties, broader tissue distribution and a more favorable safety profile..

QLi5 Therapeutics 正在开发基于一种新颖的非共价作用机制的新一代蛋白酶体抑制剂。该平台由诺贝尔奖得主罗伯特·胡伯与马克斯·普朗克生物化学研究所密切合作开发，旨在实现对蛋白酶体的高效和选择性靶向，同时提供改进的药代动力学特性、更广泛的组织分布以及更有利的安全性特征。

In October 2025, QLi5 and Qurient presented compelling preclinical research results for PI-payload-based ADCs. The results demonstrated that the PI-payload, as a novel mechanism of action, showed excellent anti-cancer efficacy in animal models that were resistant to conventional TOP1-inhibitor-based ADCs, such as Enhertu.

2025年10月，QLi5和Qurient公布了基于PI有效载荷的ADC令人信服的临床前研究结果。结果表明，PI有效载荷作为一种新的作用机制，在对传统TOP1抑制剂类ADC（如Enhertu）耐药的动物模型中显示出卓越的抗癌效果。

The potential as a 'universal payload' was also confirmed, as its efficacy is not limited to specific cancer cell types but could be demonstrated across various cell types and target models. .

其作为“通用载荷”的潜力也得到了证实，因为它的功效不仅限于特定的癌细胞类型，而且可以在各种细胞类型和靶标模型中得到验证。

The human immune system is an early riser

人体免疫系统是一个早起者

Scientists show that activation of the immune system oscillates throughout the day, with a peak just before the start of the day

科学家们展示了一天中免疫系统的激活会不断波动，并在一天开始前达到峰值。

Read news

阅读新闻

Details on Capital Increase and Strategic Alignment

资本增加和战略调整的详细信息

Now, in December 2025, QLi5 resolved to implement a capital increase totalling 6,257,600 Euro. Qurient's participation substantially increases the company's voting stake in QLi5. Particularly noteworthy is the continued participation of Robert Huber, co-founder of QLi5 and 1988 Nobel laureate in Chemistry, which underscores his deep confidence in QLi5's technological expertise and future potential. .

现在，2025年12月，QLi5决定实施总额为6,257,600欧元的增资。Qurient的参与大幅增加了其在QLi5的投票权股份。特别值得注意的是，QLi5的联合创始人、1988年诺贝尔化学奖得主罗伯特·胡贝尔继续参与其中，这充分表明了他对QLi5技术实力和未来潜力的深厚信心。

The new funds will be specifically used to advance the development of the PI-payload technology. This next-generation ADC platform represents a promising new alternative that aims to overcome the limitations of existing ADC therapeutics.

新资金将专门用于推进 PI 有效载荷技术的开发。这一下一代 ADC 平台代表着一种有前景的新替代方案，旨在克服现有 ADC 疗法的局限性。

A Strong Joint Venture with an Excellent Scientific Foundation

一个具有优秀科学基础的强大合资企业

QLi5 Therapeutics was founded as a joint venture by Qurient in collaboration with Lead Discovery Center (LDC), the Max Planck Society (MPG), and Robert Huber. Huber, a renowned structural biologist, received his Nobel Prize in Chemistry for being the first to decipher the three-dimensional structure of the proteasome, a cellular proteolytic apparatus.

QLi5治疗公司是由Qurient与Lead Discovery Center（LDC）、马克斯·普朗克学会（MPG）以及罗伯特·胡贝尔合作成立的合资企业。胡贝尔是一位著名的结构生物学家，他因首次破译蛋白酶体（一种细胞蛋白水解装置）的三维结构而获得了诺贝尔化学奖。

Building on his findings and the subsequent drug discovery work by LDC, QLi5 has developed a next-generation therapeutic approach that drastically reduces the side effects of previous proteasome inhibitors and can extend its spectrum of application to various cancer types. .

基于他的发现以及LDC随后的药物研发工作，QLi5开发了一种下一代治疗方法，这种方法大幅减少了之前蛋白酶体抑制剂的副作用，并且可以将其应用范围扩展到各种癌症类型。

Kiyean Nam, CEO of Qurient, commented: 'This capital increase is far more than mere financing; it is a strategic decision to fully unlock the enormous potential of QLi5's PI-mechanism technology as a next-generation ADC payload. With the continued support of Robert Huber and the strong network of LDC and MPG, we will accelerate development to become a gamechanger in the global ADC market.' .

Qurient公司首席执行官南基彦评论道：“此次增资远不止是融资，而是一个战略性决策，旨在充分释放QLi5的PI机制技术作为下一代ADC有效载荷的巨大潜力。在罗伯特·胡伯的持续支持以及LDC和MPG的强大网络助力下，我们将加速开发，力争成为全球ADC市场的游戏规则改变者。”

Max Planck Innovation GmbH, the central technology transfer organization of the Max Planck Society, supported the establishment of QLi5 from the outset by structuring and managing the underlying intellectual property and accompanying the company through its formation and ongoing development.

马克斯·普朗克创新有限公司（Max Planck Innovation GmbH）作为马克斯·普朗克学会的核心技术转移机构，从一开始就通过构建和管理底层知识产权，支持了QLi5的成立，并在公司组建及持续发展中提供了协助。

“Spin-offs like QLi5 exemplify how breakthrough discoveries from Max Planck research can be successfully translated into broadly applicable innovative therapeutic approaches with significant patient benefit. By combining outstanding basic science with strong industrial partnerships, QLi5 demonstrates the power of academic entrepreneurship in advancing cutting-edge biomedical innovation.”, said Ulrich Mahr, Member General Management at Max Planck Innovation GmbH..

“像QLi5这样的衍生公司展示了马克斯·普朗克研究所的突破性发现如何成功转化为具有广泛适用性的创新治疗方案，并为患者带来显著益处。通过将卓越的基础科学研究与强大的产业合作相结合，QLi5展现了学术创业在推动前沿生物医学创新方面的力量。” 马克斯·普朗克创新有限公司总经理乌尔里希·马尔表示。

Dieter Link, Senior Patenting & Licensing Manager at Max Planck Innovation added: “Professor Huber’s pioneering insights into the structure and function of the proteasome have enabled the development and various applications of a new class of proteasome inhibitors. The current financing provides the resources needed to further advance this technology and translate it into differentiated therapeutic applications.”.

迪特·林克（Dieter Link），马克斯·普朗克创新公司的高级专利与授权经理补充道：“胡贝尔教授在蛋白酶体结构与功能方面的开创性见解，推动了新一代蛋白酶体抑制剂的开发和多种应用。当前的融资为推进这项技术并将其转化为差异化的治疗应用提供了所需资源。”

https://www.bionity.com/en/news/1187984/max-planck-spin-off-qli5-receives-multi-million-euro-investment-from-qurient-therapeutics.html

Building block of 'happiness hormone' is key to controlling immunity in cancer and auto-immune diseases

“幸福荷尔蒙”的构建块是控制癌症和自身免疫疾病中免疫力的关键

Read news

读新闻